Beovu

Showing 3 posts of 3 posts found.

Novartis’ Beovu approved in Europe after outclassing Eylea in wet age-related macular degeneration

February 18, 2020
Manufacturing and Production, Sales and Marketing Beovu, Eylea, Novartis, Regeneron, macular degeneration, pharma

The European Commission (EC) has chosen to approve Novartis’ Beovu (brolucizumab) injection, it has emerged, as a treatment for wet …

novartis_window

Novartis’ Beovu scores CHMP recommendation after proving non-inferior to Eylea in wet age-related macular degeneration

December 13, 2019
Medical Communications, Sales and Marketing Beovu, EMA, Novartis, pharma

Novartis’ single-chain antibody fragment Beovu has secured recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use …

novartis_outside_1

FDA approves Novartis’ Beovu injection for wet age-related macular degeneration

October 8, 2019
Manufacturing and Production, Sales and Marketing Beovu, Eylea, FDA, Novartis, Regeneron, pharma

Novartis has secured FDA approval for its Beovu (brolucizumab) injection in the treatment of wet age-related macular degeneration (AMD), it …

Latest content